Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET END USERS COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 EPIDEMIOLOGY
4.2 PESTEL ANALYSIS
4.3 PORTER’S FIVE FORCES MODEL
5 INSURANCE AND REIMBURSEMENT - NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
5.1 U.S.
5.2 CANADA
6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: REGULATIONS
6.1 REGULATION IN THE U.S.
7 MARKET OVERVIEW
7.1 DRIVERS
7.1.1 INCREASE IN INCIDENCE OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
7.1.2 RISE IN AIR POLLUTION AND SURGE IN SMOKING
7.1.3 HIGH INCIDENCE OF CHRONIC DISEASES
7.1.4 RISE IN CLINICAL TRIALS
7.1.5 INCREASING DRUG APPROVALS
7.2 RESTRAINTS
7.2.1 LESS NUMBER OF DONORS FOR ORGAN DONATION
7.2.2 HIGH COST OF ORGAN TRANSPLANTATION
7.3 OPPORTUNITIES
7.3.1 RISING HEALTHCARE SPENDING
7.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
7.3.3 TECHNOLOGICAL ADVANCEMENTS IN LUNG TRANSPLANTATION
7.4 CHALLENGES
7.4.1 STRINGENT REGULATORY FRAMEWORK
7.4.2 COMPLICATIONS ASSOCIATED WITH LUNG TRANSPLANTATION
8 IMPACT OF COVID-19 ON LUNG TRANSPLANT THERAPEUTICS MARKET
8.1 IMPACT ON PRICE
8.2 IMPACT ON DEMAND
8.3 IMPACT ON SUPPLY CHAIN
8.4 STRATEGIC INITIATIVES
8.5 CONCLUSION
9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT
9.1 OVERVIEW
9.2 IMMUNOSUPPRESSANT DRUGS
9.2.1 BY CLASS
9.2.1.1 CALCINEURIN INHIBITORS
9.2.1.1.1 TACROLIMUS
9.2.1.1.2 CYCLOSPORIN
9.2.1.2 ANTIMETABOLITE IMMUNOSUPPRESANTS
9.2.1.2.1 MYCOPHENOLATE MOFETIL
9.2.1.2.2 MYCOPHENOLATE SODIUM
9.2.1.2.3 AZATHIOPRINE
9.2.1.3 M-TOR INHIBITOR
9.2.1.3.1 SIROLIMUS
9.2.1.3.2 EVEROLIMUS
9.2.1.4 STEROIDS
9.2.1.4.1 METHYLPREDNISOLONE
9.2.1.4.2 PREDNISONE
9.2.1.5 MONOCLONAL ANTIBODY
9.2.1.5.1 BASILIXIMAB
9.2.1.5.2 MUROMONAB
9.2.1.6 OTHERS
9.2.2 BY DRUG TYPE
9.2.2.1 BRANDED
9.2.2.2 GENERIC
9.2.3 ROUTE OF ADMINISTRATION
9.2.3.1 ORAL ADMINISTRATION
9.2.3.2 PARENTERAL ADMINISTRATION
9.3 ORGAN PRESERVATION PRODUCTS
9.3.1 PERFADEX
9.3.2 HUMAN BIOSYSTEM (HBS) SOLUTION
9.3.3 LIFOR
9.3.4 CUSTODIOL HTK-(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) SOLUTION
9.3.5 RENOGRAF
9.3.6 OTHERS
9.4 TISSUE PRODUCT
9.5 OTHERS
10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE
10.1 OVERVIEW
10.2 SINGLE-LUNG TRANSPLANT (SLT)
10.3 DOUBLE LUNG TRANSPLANT
10.4 BILATERAL LUNG TRANSPLANT (BLT)
10.5 HEART-LUNG TRANSPLANT
11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS
11.1 OVERVIEW
11.2 ADULTS
11.3 GERIATRIC
11.4 PEDIATRIC
12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE
12.1 OVERVIEW
12.2 CADAVERIC LUNG TRANSPLANT
12.3 LIVING LUNG TRANSPLANT
13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION
13.1 OVERVIEW
13.2 CYSTIC FIBROSIS
13.3 PULMONARY FIBROSIS
13.4 CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
13.5 INTERSTITIAL PULMONARY FIBROSIS
13.6 PULMONARY HYPERTENSION
13.7 PRIMARY PULMONARY ARTERIAL HYPERTENSION
13.8 EMPHYSEMA
13.9 SARCOIDOSIS
13.1 SEPTIC LUNG DISEASE
13.11 OTHERS
14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITAL
14.3 TRANSPLANT CENTERS
14.4 SPECIALTY CENTERS
14.5 OTHERS
15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY
15.1 OVERVIEW
15.1.1 U.S.
15.1.2 CANADA
15.1.3 MEXICO
16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: NORTH AMERICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 ASTELLAS PHARMA INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 PRODUCT PORTFOLIO
18.1.4 RECENT DEVELOPMENT
18.2 TRANSMEDICS (A SUBSIDIARY OF TRANSMEDICS GROUP, INC)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENT
18.3 DR. REDDY’S LABORATORIES LTD.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 F.HOFFMANN-LA ROCHE LTD.
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 HIKMA PHARMACEUTICALS PLC
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 COMPANY SHARE ANALYSIS
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENT
18.6 APOTEX INC
18.6.1 COMPANY SNAPSHOT
18.6.2 PRODUCT PORTFOLIO
18.6.3 RECENT DEVELOPMENT
18.7 XVIVO
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 ACCORD-UK LTD
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 BIOLIFE SOLUTIONS
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENT
18.1 BRIDGE TO LIFE LTD
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 DETRAXI, INC.
18.11.1 COMPANY SNAPSHOT
18.11.2 PRODUCT PORTFOLIO
18.11.3 RECENT DEVELOPMENT
18.12 INTAS PHARMACEUTICALS LTD.
18.12.1 COMPANY SNAPSHOT
18.12.2 PRODUCT PORTFOLIO
18.12.3 RECENT DEVELOPMENT
18.13 NOVARTIS AG
18.13.1 COMPANY SNAPSHOT
18.13.2 REVENUE ANALYSIS
18.13.3 PRODUCT PORTFOLIO
18.13.4 RECENT DEVELOPMENT
18.14 PANACEA BIOTEC LTD.
18.14.1 COMPANY SNAPSHOT
18.14.2 REVENUE ANALYSIS
18.14.3 PRODUCT PORTFOLIO
18.14.4 RECENT DEVELOPMENT
18.15 PARAGONIX TECHNOLOGIES, INC
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENTS
18.15.3.1 PRODUCT LAUNCH
18.15.3.2 PARTNERSHIP
18.16 PFIZER INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENT
18.17 VIATRIS, INC
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENT
18.18 21ST CENTURY MEDICINE
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
List of Table
TABLE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 2 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 3 NORTH AMERICA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 4 NORTH AMERICA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 5 NORTH AMERICA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 6 NORTH AMERICA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 7 NORTH AMERICA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 8 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 9 NORTH AMERICA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 10 NORTH AMERICA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 11 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 12 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 13 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET, BY COUNTRY, 2020-2029 (USD MILLION)
TABLE 17 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 18 U.S. IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 19 U.S. CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 20 U.S. ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 21 U.S. M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 22 U.S. STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 23 U.S. MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 24 U.S. IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 25 U.S. IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 26 U.S. ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 27 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 28 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 29 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 30 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 31 U.S. LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 32 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 33 CANADA IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 34 CANADA CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 35 CANADA ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 36 CANADA M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 37 CANADA STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 38 CANADA MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 39 CANADA IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 40 CANADA IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 41 CANADA ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 42 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 43 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 44 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 45 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 46 CANADA LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
TABLE 47 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 48 MEXICO IMMUNOSUPPRESSANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 49 MEXICO CALCINEURIN INHIBITORS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 50 MEXICO ANTIMETABOLITE IMMUNOSUPPRESANTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 51 MEXICO M-TOR INHIBITOR IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 52 MEXICO STEROIDS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 53 MEXICO MONOCLONAL ANTIBODY IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY CLASS, 2020-2029 (USD MILLION)
TABLE 54 MEXICO IMMUNOSUPRRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)
TABLE 55 MEXICO IMMUNOSUPPRESANT DRUGS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)
TABLE 56 MEXICO ORGAN PRESERVATION PRODUCTS IN LUNG TRANSPLANT THERAPEUTICS MARKET, BY PRODUCT, 2020-2029 (USD MILLION)
TABLE 57 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY INDICATION, 2020-2029 (USD MILLION)
TABLE 58 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TYPE, 2020-2029 (USD MILLION)
TABLE 59 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY TECHNIQUE, 2020-2029 (USD MILLION)
TABLE 60 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
TABLE 61 MEXICO LUNG TRANSPLANT THERAPEUTICS MARKET, BY END USER, 2020-2029 (USD MILLION)
List of Figure
FIGURE 1 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 2 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DATA TRIANGULATION
FIGURE 3 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DROC ANALYSIS
FIGURE 4 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: MARKET END USERS COVERAGE GRID
FIGURE 8 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: DBMR VENDOR SHARE ANALYSIS
FIGURE 10 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SEGMENTATION
FIGURE 11 TECHNOLOGICAL ADVANCEMENTS IN HEALTHCARE AND SURGICAL SEGMENTS ASSOCIATED WITH ORGAN TRANSPLANTATION IS EXPECTED TO DRIVE THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN THE FORECAST PERIOD OF 2022 TO 2029
FIGURE 12 IMMUNOSUPPRESSANTS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET IN 2022 & 2029
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET
FIGURE 14 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2021
FIGURE 15 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, 2020-2029 (USD MILLION)
FIGURE 16 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, CAGR (2022-2029)
FIGURE 17 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT, LIFELINE CURVE
FIGURE 18 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2021
FIGURE 19 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, 2020-2029 (USD MILLION)
FIGURE 20 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, CAGR (2022-2029)
FIGURE 21 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TECHNIQUE, LIFELINE CURVE
FIGURE 22 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2021
FIGURE 23 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, 2020-2029 (USD MILLION)
FIGURE 24 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, CAGR (2022-2029)
FIGURE 25 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PATIENT DEMOGRAPHICS, LIFELINE CURVE
FIGURE 26 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2021
FIGURE 27 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, 2022-2029 (USD MILLION)
FIGURE 28 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, CAGR (2022-2029)
FIGURE 29 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY TYPE, LIFELINE CURVE
FIGURE 30 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2021
FIGURE 31 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, 2020-2029 (USD MILLION)
FIGURE 32 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, CAGR (2022-2029)
FIGURE 33 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY INDICATION, LIFELINE CURVE
FIGURE 34 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2021
FIGURE 35 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, 2020-2029 (USD MILLION)
FIGURE 36 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, CAGR (2022-2029)
FIGURE 37 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET : BY END USER, LIFELINE CURVE
FIGURE 38 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: SNAPSHOT (2021)
FIGURE 39 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021)
FIGURE 40 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2022 & 2029)
FIGURE 41 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY COUNTRY (2021 & 2029)
FIGURE 42 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: BY PRODUCT (2022-2029)
FIGURE 43 NORTH AMERICA LUNG TRANSPLANT THERAPEUTICS MARKET: COMPANY SHARE 2021 (%)
